Advances in the treatment of elderly patients with multiple myeloma
Facon, T.
Clinical Advances in Hematology and Oncology H&o 4(7): 501-502
2006
ISSN/ISBN: 1543-0790 PMID: 17147234 Document Number: 604778
Document emailed within 1 workday
Related Documents
Clavio, M.; Casciaro, S.; Gatti, A.M.; Spriano, M.; Bonanni, F.; Poggi, A.; Vallebella, E.; Pietrasanta, D.; Prencipe, E.; Goretti, R.; Vimercati, R.; Rossi, E.; Masoudi, B.; Ghio, R.; Boccaccio, P.; Ricciardi, S.; Damasio, E.; Gobbi, M. 1996: Multiple myeloma in the elderly: clinical features and response to treatment in 113 patients Haematologica 81(3): 238-244Dimopoulos, M.A.; Anagnostopoulos, A.; Terpos, E.; Repoussis, P.; Zomas, A.; Katodritou, E.; Kyrtsonis, M.Christine.; Delibasi, S.; Vassou, A.; Pouli, A.; Zervas, K.; Anagnostopoulos, N.; Maniatis, A. 2006: Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma Haematologica 91(2): 252-254
Barlogie, B.; Alexanian, R. 1989: Second International Workshop on Myeloma: advances in biology and therapy of multiple myeloma Cancer Research 49(24 Pt 1): 7172-7175
Weber, D.M. 2003: Strategies in treating newly diagnosed or untreated multiple myeloma patients. from the Multiple Myeloma Research Foundation Oncology 17(6): 765-767
Kurtin, S. 2011: Advances and new challenges in multiple myeloma Oncology 25(4 Suppl Nurse Ed): 33-34
Klein, B.; Bataille, R. 1990: Advances in the biology of multiple myeloma Pathologie-Biologie 38(8): 820-821
Varterasian, M.L. 1995: Biologic and clinical advances in multiple myeloma Oncology 9(5): 417
Miwa, A. 2007: Advances in therapeutic strategies for multiple myeloma Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(13): 2200-2216
Kosaka, M. 1996: Advances in the pathogenesis, biology, and management of multiple myeloma Rinsho Byori. Japanese Journal of Clinical Pathology 44(8): 743-749
Stevenson, F.; Anderson, K.C. 1999: Introduction: immunotherapy for multiple myeloma--insights and advances Seminars in Hematology 36(1 Suppl. 3): 1-2
Vulić, D.; Radlović, O.; Stanojcić, A.; Radmilović, A.; Rajić, M. 1996: Treatment of renal insufficiency in patients with multiple myeloma Srpski Arhiv Za Celokupno Lekarstvo 124(Suppl 1): 53-55
2009: Thalidomide: new indication. For elderly myeloma patients: some improvement in first-line treatment Prescrire International 18(100): 49-52
Adam, Z.; Krahulová, M.; Spelda, S.; Vorlícek, J.; Hejlová, N.; Hájek, R.; Tomíska, M. 1995: Evaluation of treatment of anemia with erythropoietin in patients with multiple myeloma Vnitrni Lekarstvi 41(11): 767-772
Wölfler, A.; Bauer, F.; Zollner, G.; Weber, K.; Sill, H.; Linkesch, W. 2003: Fatal sepsis after thalidomide/dexamethasone treatment in two patients with multiple myeloma Haematologica 88(4): Elt12
García Laraña, J.; Díaz Mediavilla, J.; Martínez, R.; Lahuerta, J.J.; Alegre, A.; Odriozola, J.; Sureda, A.; San Miguel, J.; De la Rubia, J.; Escudero, A.; Conde, E.; Bladé, J.; Cabrera, R.; Gastearena, J.; Besalduch, J.; Vidal, M.J.; Hernández, F.; Rifon, J.; Leon, A.; Mataix, R.; Parody, R.; Moraleda, J.M.; Solano, C.; de Pablos, J.M.; Sánchez, J.J. 1997: Maintenance treatment with interferon-alfa in multiple myeloma after autotransplantation of peripheral blood progenitor cells. Spanish Register of Transplantation in Myeloma Sangre 42(Suppl 1): 38-41
Spicka, I.; Svára, F.; Novosadová, L.; Mácel, I.; Válková, V.; Sulková, S.; Merta, M.; Klener, P. 1997: Effect of treatment with recombinant erythropoietin in patients with multiple myeloma and kidney failure Sbornik Lekarsky 98(2): 127-133
Dimopoulos, M.A.; Kastritis, E.; Anagnostopoulos, A.; Melakopoulos, I.; Gika, D.; Moulopoulos, L.A.; Bamia, C.; Terpos, E.; Tsionos, K.; Bamias, A. 2006: Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid Haematologica 91(7): 968-971
Bataille, R.; Morlock, G.; Rosenberg, F.; Sany, J.; Serre, H. 1978: Evaluation of the tumor mass and its regression under treatment of multiple myeloma of the bones. Critical comments apropos of 22 patients Revue du Rhumatisme et des Maladies Osteo-Articulaires 45(1): 1-5
Joffe, J.K.; Bell, J.B.; Denham, S.; Adshead, F.; Millar, J.L.; Millar, B.C. 1995: G-CSF is a major component of colony-stimulating activity (CSA) in the plasma of patients with multiple myeloma after treatment with high-dose melphalan (HDM) Experimental Hematology 23(4): 376-382
Teunissen, L.L.; Notermans, N.C. 1998: The risk of Kahler disease (multiple myeloma) in patients with a paraproteinemia: myeloma risk score, developed in the region of the Integral Cancer Center, West Nederlands Tijdschrift Voor Geneeskunde 142(43): 2374-2375